My Profile
Edit Profile
My Follows
My Wires
My Drafts
Analytics
Email Preferences
Sign Out
home
most popular
Latest
Buy Hold Sell
Alternatives In Focus
Series
Alternatives in Focus
Buy Hold Sell
Expert Insights
Fund in Focus
Income Series
Listed Series
Livewire Live
Meet The Adviser
Meet The Investor
Outlook Series
Rapid Fire
Reporting Season
Signal or Noise
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Undiscovered Funds
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Contributors
Find Funds
Newsletter
About Livewire
Advertising
Careers
Contact Us
Write a Wire
Notifications
Loading...
Write a wire
Account
My profile
My follows
My wires
My drafts
Analytics
Email preferences
Company
About Livewire
Advertising
Contact us
Sign out
Sign In
Join Free
Latest
Buy Hold Sell
Alternatives In Focus
Series
Alternatives in Focus
Buy Hold Sell
Fund in Focus
Income Series
Livewire Live
Meet The Investor
Rapid Fire
Signal or Noise
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Find funds
Newsletter
mesoblast
Latest news and analysis on mesoblast
Equities
August 31, 2020 16:48
Game changing potential for loss-making Mesoblast
Melbourne-based biotech Mesoblast will achieve a world-first that could open up its drug pipeline to a massive market if it wins US Food and Drug Administration...
Glenn Freeman
Livewire Markets
August 31, 2020 16:48
September 27, 2016 14:28
A biotech that's been
misunderstood
MSB
Mesoblast Ltd
ASX:MSB
Followed by
315
people
MSB
Mesoblast Ltd
ASX:MSB
Followed by
315
people
Livewire Exclusive
Livewire Markets
September 27, 2016 14:28
September 06, 2016 06:41
Mesoblast (ASX: MSB) - Why I expect Team Silviu can make a strong comeback
Stuart Roberts
Pitt Street Research and NDF Research
September 06, 2016 06:41
Advertisement
November 24, 2013 22:52
Legislation just passed in Japan could accelerate Mesoblast's (MSB) entry into the largest market outside of the US
James Marlay
Livewire Markets
November 24, 2013 22:52
4
most
popular
Equities
Decade of excellence: 10 years of outstanding performance for L1 Capital’s Long Short Fund
Chris Conway,
Livewire Markets
Equities
The 7 zombie companies lurking on the ASX 300
Ally Selby,
Livewire Markets
Equities
Buy Hold Sell: The best and worst investment ideas from 5 ASX
sectors
Buy Hold Sell,
Livewire Markets
Education
Warren Buffett’s 25 biggest mistakes – and 4 lessons they teach
Chris Leithner,
Leithner & Company Ltd
view all
Advertisement
